Canaccord analyst William Plovanic raised the firm’s price target on Stryker to $360 from $315 and keeps a Buy rating on the shares. The firm said they delivered a strong Q4 in the face of a tough Q4/22 comp, beating on the top and bottom lines and continuing to note healthy capital demand.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SYK: